A Meta-Analysis of Resveratrol Protects against Myocardial Ischemia/Reperfusion Injury: Evidence from Small Animal Studies and Insight into Molecular Mechanisms
Table 6
Stratified analysis of pooled estimates of infarct size in vivo and ex vivo.
Pooled estimates
No. of studies
WMD (95% CI)
value
In vivo studies
Reperfusion duration
<24 h
8
-12.26 (-15.67, -8.84)
≤0.001
≥24 h
2
-22.15 (-36.52, -7.77)
0.003
Route of administration
i.p.
4
-20.57 (-26.81, -14.33)
≤0.001
i.v.
6
-10.14 (-11.98, -8.29)
≤0.001
Timing regimen of pretreatment
≥60 min
4
-20.57 (-26.81, -14.33)
≤0.001
<60 min
6
-10.14 (-11.98, -8.29)
≤0.001
Overall
10
-13.42 (-16.63, -10.21)
≤0.001
Ex vivo studies
Reperfusion duration
≤1 h
3
-15.38 (-21.93, -8.82)
≤0.001
>1 h
4
-15.06 (-19.15, -10.96)
≤0.001
Route of administration
Perfusion
4
-17.75 (-23.11, -12.40)
≤0.001
Gavage
3
-12.92 (-16.70, -9.14)
≤0.001
Timing regimen of pretreatment
≥60 min
3
-12.92 (-16.70, -9.14)
≤0.001
<60 min
4
-17.75 (-23.11, -12.40)
≤0.001
Overall
7
-15.05 (-18.23, -11.86)
≤0.001
Stratified analysis investigated whether particular categorical covariates explain any of the heterogeneity of treatments between studies.
